The Development of Immune-based Therapies Using Plant Derived Compounds to Attenu

描述（由申请人提供）：从特定植物材料中提取次生代谢物，以鉴定和分离免疫活性成分。这些成分被认为是在人类免疫缺陷病毒（HIV）发展为获得性免疫缺陷综合征（AIDS）发生之前，通过调节白细胞中的某些细胞因子水平来增强先天和适应性免疫系统。确定的成分将用于开发新的抗艾滋病毒免疫疗法。已鉴定出含有具有理想免疫活性特性的组分的植物材料。建立了适合于从植物材料中提取次生代谢物（非聚合小分子）和基于抗体的白细胞细胞因子检测方法。该项目的第一阶段包括利用反相高效液相色谱法（HPLC）、离子交换色谱法（IEC）、核磁共振（NMR）和质谱法（MS）从植物提取物中鉴定和分离免疫活性成分。将确定植物中有效成分的百分比。该项目的第二阶段将需要大规模分离/纯化或合成已确定的免疫活性植物成分，以在体外和体内开发新的抗艾滋病毒免疫疗法。提出的治疗方法可以降低病毒载量，间接降低HIV对当前抗病毒药物的耐药性。

DESCRIPTION (provided by applicant): Secondary metabolites will be extracted from a specific plant material to identify and isolate immune active components. These components are proposed to enhance the innate and adaptive immune systems by modulating certain cytokine levels in white blood cells before the progression of Human Immunodeficiency Virus (HIV) to Acquired Immune Deficiency Syndrome (AIDS) occurs. The components identified will be used to develop new anti-HIV immune-based therapies. The plant material containing the components with desirable immune active characteristics has been identified. The methods suitable for extraction of secondary metabolites (non-polymeric small molecules) from the plant material and antibody-based assay for testing of human cytokines in white blood cells have been established. Phase I of this project includes identification and isolation of immune active components from the plant extract using reverse phase High Performance Liquid Chromatography (HPLC), Ion-Exchange Chromatography (IEC), Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS). The percentage of active components in the plant will be determined. Phase II of the project will entail either large scale isolation/purification or synthesis of identified immune active plant components to develop screens for new anti-HIV immune-based therapies both in vitro and in vivo. The therapies proposed can reduce viral load and indirectly lower the resistance of HIV to current antiviral drugs. PUBLIC HEALTH RELEVANCE: The project seeks to isolate immune active components from specific plants that can modulate certain cytokine levels in human white blood cells which would provide an immune-based therapeutic activity to attenuate HIV progression. The end result of this project would have substantial commercial potential as a frontline therapy and synergistic compound that can indirectly lower the resistance of HIV to current antiviral drugs. We believe that our potential product will be used either alone, as an initial therapy for newly diagnosed patients, or in combination with current antiviral drugs.